Susceptibility of human Plasmodium knowlesi infections to anti-malarials

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Fatih, Farrah A ^a   Staines, Henry M ^a   Siner, Angela ^b   Ahmed, Mohammed Atique ^b   Woon, Lu Chan ^c   Pasini, Erica M ^d   Kocken, Clemens Hm ^d   Singh, Balbir ^b   Cox Singh, Janet ^b,e   Krishna, Sanjeev ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITI MALAYSIA SARAWAK   (Malaysia)

^c Pathology Laboratory   (Malaysia)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^e UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Artemether; Artemisinin; Artesunate; Chloroquine; DHA; Dihydroartemisinin; Malaria; Mefloquine

Indexed keywords

ARTEMISININ DERIVATIVE; CHLOROQUINE; LACTATE DEHYDROGENASE; MEFLOQUINE;

ANIMAL CELL; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; BIOASSAY; BORNEO; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIFE CYCLE; NONHUMAN; PARASITE DEVELOPMENT; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM VIVAX; POINT MUTATION; SCHIZONT; SCHIZONT MATURATION ASSAY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BORNEO; CHLOROQUINE; HUMANS; MALARIA; MEFLOQUINE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM VIVAX; ZOONOSES;

EID: 84887716187     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-425     Document Type: Article

References (36)

1. Human infections and detection of Plasmodium knowlesi. Singh B, Daneshvar C, Clin Microbiol Rev 2013 26 165 184
2. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh J, Thomas A, Conway DJ, Lancet 2004 363 1017 1024 (Pubitemid 38410774)
3. Natural transmission of Plasmodium knowlesi to humans by Anopheles latens in Sarawak, Malaysia. Vythilingam I, Tan CH, Asmad M, Chan ST, Lee KS, Singh B, Trans R Soc Trop Med Hyg 2006 100 1087 1088 (Pubitemid 44309212)
4. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B, Clin Infect Dis 2008 46 165 171 (Pubitemid 351269152)
5. Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax malaria in Sabah, Malaysia. William T, Rahman HA, Jelip J, Ibrahim MY, Menon J, Grigg MJ, Yeo TW, Anstey NM, Barber BE, PLoS Negl Trop Dis 2013 7 2026
6. Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques. Lee KS, Divis PC, Zakaria SK, Matusop A, Julin RA, Conway DJ, Cox-Singh J, Singh B, PLoS Pathog 2011 7 1002015
7. WHO Mark III assay http://www.who.int/malaria/publications/atoz/markiii. pdf
8. Time course of in vitro maturation of intra-erythrocytic malaria parasite: a comparison between Plasmodium falciparum and Plasmodium knowlesi. Srinivas SD, Puri SK, Mem Inst Oswaldo Cruz 2002 97 901 903 (Pubitemid 135745945)
9. In vitro drug sensitivity testing in Plasmodium vivax. Wernsdorfer WH, Tasanor O, Wernsdorfer G, Wien Klin Wochenschr 2008 120 30 33
10. Antigenic variation of Plasmodium knowlesi malaria: identification of the variant antigen on infected erythrocytes. Howard RJ, Barnwell JW, Kao V, Proc Natl Acad Sci U S A 1983 80 4129 4133
11. Plasmodium knowlesi provides a rapid in vitro and in vivo transfection system that enables double-crossover gene knockout studies. Kocken CH, Ozwara H, van der Wel A, Beetsma AL, Mwenda JM, Thomas AW, Infect Immun 2002 70 655 660 (Pubitemid 34083824)
12. A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Druilhe P, Moreno A, Blanc C, Brasseur PH, Jacquier P, Am J Trop Med Hyg 2001 64 233 241
13. Molecular markers of Plasmodium resistance to antimalarials. Ecker A, Lehane AM, Fiddock DA, Treatment and Prevention of Malaria: Antimalarial Drug Chemistry, Action and Use Basel: Springer Basel, Staines HM, Krishna S, 2012 249 280
14. PlasmoDB http://www.plasmodb.org/plasmo/
15. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, Antimicrob Agents Chemother 1979 16 710 718 (Pubitemid 10082023)
16. Expression in yeast links field polymorphisms in PfATP6 to in vitro artemisinin resistance and identifies new inhibitor classes. Pulcini S, Staines HM, Pittman JK, Slavic K, Doerig C, Halbert J, Tewari R, Shah F, Avery MA, Haynes RK, Krishna S, J Infect Dis 2013 in press
17. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, East M, Lee A, Brady L, Haynes RK, Krishna S, Nat Struct Mol Biol 2005 12 628 629 (Pubitemid 40980816)
18. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S, Antimicrob Agents Chemother 2010 54 3842 3852
19. Plasmodium cynomolgi genome sequences provide insight into Plasmodium vivax and the monkey malaria clade. Tachibana S, Sullivan SA, Kawai S, Nakamura S, Kim HR, Goto N, Arisue N, Palacpac NM, Honma H, Yagi M, Tougan T, Katakai Y, Kaneko O, Mita T, Kita K, Yasutomi Y, Sutton PL, Shakhbatyan R, Horii T, Yasunaga T, Barnwell JW, Escalante AA, Carlton JM, Tanabe K, Nat Genet 2012 44 1051 1055
20. Expansion of host cellular niche can drive adaptation of a zoonotic malaria parasite to humans. Lim C, Hansen E, DeSimone TM, Moreno Y, Junker K, Bei A, Brugnara C, Buckee CO, Duraisingh MT, Nat Commun 2013 4 1638
21. Adaptation of the genetically tractable malaria pathogen Plasmodium knowlesi to continuous culture in human erythrocytes. Moon RW, Hall J, Rangkuti F, Ho YS, Almond N, Mitchell GH, Pain A, Holder AA, Blackman MJ, Proc Natl Acad Sci U S A 2013 110 531 536
22. A prospective comparative study of knowlesi, falciparum, and vivax malaria in sabah, malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, Anstey NM, Yeo TW, Clin Infect Dis 2013 56 383 397
23. Therapeutic efficacy of naphthoquine phosphate combined with artemisinine against Plasmodium knowlesi. Wang JY, Ding DB, Li GF, Zhao JH, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2008 26 442 444
24. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. William T, Menon J, Rajahram G, Chan L, Ma G, Donaldson S, Khoo S, Frederick C, Jelip J, Anstey NM, Yeo TW, Emerg Infect Dis 2011 17 1248 1255
25. Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay. Co EM, Dennull RA, Reinbold DD, Waters NC, Johnson JD, Antimicrob Agents Chemother 2009 53 2557 2563
26. Chemosensitizing action of cepharanthine against drug-resistant human malaria, Plasmodium falciparum. Tamez PA, Lantvit D, Lim E, Pezzuto JM, J Ethnopharmacol 2005 98 137 142 (Pubitemid 40349178)
27. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF, Am J Trop Med Hyg 1998 58 630 637 (Pubitemid 28237263)
28. Molecular epidemiology of malaria in cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Basco LK, Am J Trop Med Hyg 2004 70 474 480 (Pubitemid 38658140)
29. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Daneshvar C, Davis TM, Cox-Singh J, Rafa'ee MZ, Zakaria SK, Divis PC, Singh B, Malar J 2010 9 238
30. Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections. Tyagi RK, Das MK, Singh SS, Sharma YD, J Antimicrob Chemother 2013 68 1081 1088
31. Antimalarial drug susceptibility testing of Plasmodium falciparum in Brazil using a radioisotope method. Cerutti Junior C, Marques C, Alencar FE, Durlacher RR, Alween A, Segurado AA, Pang LW, Zalis MG, Mem Inst Oswaldo Cruz 1999 94 803 809 (Pubitemid 129618929)
32. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR, Antimicrob Agents Chemother 2003 47 2418 2423 (Pubitemid 36919439)
33. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S, Antimicrob Agents Chemother 1999 43 2943 2949
34. Mefloquine resistance reversal action of ketoconazole-a cytochrome P450 inhibitor, against mefloquine-resistant malaria. Tripathi R, Awasthi A, Dutta GP, Parasitology 2005 130 475 479 (Pubitemid 40685761)
35. Plasmodium knowlesi reinfection in human. Lau YL, Tan LH, Chin LC, Fong MY, Noraishah MA, Rohela M, Emerg Infect Dis 2011 17 1314 1315
36. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S, Lancet 2004 364 438 447 (Pubitemid 39036891)